Hannah C Timmins1, David Mizrahi2, Tiffany Li1, Matthew C Kiernan1,3,4, David Goldstein2,5, Susanna B Park6. 1. Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. 2. Prince of Wales Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia. 3. Sydney Medical School, The University of Sydney, Sydney, Australia. 4. Royal Prince Alfred Hospital, Camperdown, Australia. 5. Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia. 6. Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. susanna.park@sydney.edu.au.
Abstract
PURPOSE: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. METHODS: Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. RESULTS: Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. CONCLUSIONS: Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
PURPOSE: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. METHODS: Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. RESULTS: Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. CONCLUSIONS: Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
Authors: Mark H Ebell; Jay Siwek; Barry D Weiss; Steven H Woolf; Jeffrey Susman; Bernard Ewigman; Marjorie Bowman Journal: Am Fam Physician Date: 2004-02-01 Impact factor: 3.292
Authors: Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek Journal: Diabetes Metab Res Rev Date: 2010-05 Impact factor: 4.876
Authors: J Furlanetto; W Eiermann; F Marmé; T Reimer; M Reinisch; S Schmatloch; E Stickeler; C Thomssen; M Untch; C Denkert; G von Minckwitz; B Lederer; V Nekljudova; K Weber; S Loibl; V Möbus Journal: Ann Oncol Date: 2016-08-08 Impact factor: 32.976
Authors: Jetter Robertson; Jeffrey Raizer; James S Hodges; William Gradishar; Jeffrey A Allen Journal: J Peripher Nerv Syst Date: 2018-05-11 Impact factor: 3.494
Authors: Brian C Callaghan; Rong Xia; Evan Reynolds; Mousumi Banerjee; Amy E Rothberg; Charles F Burant; Emily Villegas-Umana; Rodica Pop-Busui; Eva L Feldman Journal: JAMA Neurol Date: 2016-12-01 Impact factor: 18.302
Authors: Myra Barginear; Amylou C Dueck; Jacob B Allred; Craig Bunnell; Harvey J Cohen; Rachel A Freedman; Arti Hurria; Gretchen Kimmick; Jennifer G Le-Rademacher; Stuart Lichtman; Hyman B Muss; Lawrence N Shulman; M Sitiki Copur; David Biggs; Bhuvaneswari Ramaswamy; Jacqueline M Lafky; Aminah Jatoi Journal: Oncologist Date: 2018-11-08
Authors: Willemieke P M Dijksterhuis; Maarten J Pruijt; Stephanie O van der Woude; Remy Klaassen; Sophie A Kurk; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910
Authors: Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan Journal: Pharmaceuticals (Basel) Date: 2022-05-15
Authors: Astrid Lahousse; Eva Roose; Laurence Leysen; Sevilay Tümkaya Yilmaz; Kenza Mostaqim; Felipe Reis; Emma Rheel; David Beckwée; Jo Nijs Journal: J Clin Med Date: 2021-12-30 Impact factor: 4.241
Authors: Sevilay Tümkaya Yılmaz; Anneleen Malfliet; Ömer Elma; Tom Deliens; Jo Nijs; Peter Clarys; An De Groef; Iris Coppieters Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241
Authors: Natalia Mitin; Kirsten A Nyrop; Susan L Strum; Anne Knecht; Lisa A Carey; Katherine E Reeder-Hayes; E Claire Dees; Trevor A Jolly; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Erin A O'Hare; Hyman B Muss Journal: NPJ Breast Cancer Date: 2022-09-08